(6-bromo-pyrazolo[1,5-a]pyridin-2-yl)-(6-methyl-8,9-dihydro-6H-furo[3,2-f]isoquinolin-7-yl)-methanone | 1176517-65-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (6-bromo-pyrazolo[1,5-a]pyridin-2-yl)-(6-methyl-8,9-dihydro-6H-furo[3,2-f]isoquinolin-7-yl)-methanone
• 英文别名: (6-bromopyrazolo[1,5-a]pyridin-2-yl)-(6-methyl-8,9-dihydro-6H-furo[3,2-f]isoquinolin-7-yl)methanone
• CAS: 1176517-65-9
• 化学式: C₂₀H₁₆BrN₃O₂
• 分子量: 410.27
• InChiKey: UYNVPEACYYHNEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2090576A1

  公开（公告）日：2009-08-19

  The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. wherein A represents -NR3R4 with R3 and R4 as described herein.

  本发明涉及式（I）的6-卤代吡唑并[1,5-a]吡啶以及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。 其中，A表示-NR3R4，其中R3和R4如本文所述。
• [EN] 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS<br/>[FR] 6-HALO-PYRAZOLO[1,5-A]PYRIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE (MGLUR)
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095253A1

  公开（公告）日：2009-08-06

  The invention relates to 6-halo-pyrazolo[1, 5-a] pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.